Back to search

Safety and antitumor activity of the PARP inhibitor BMN673 in a phase 1 trial recruiting metastatic small-cell lung cancer (SCLC) and germline BRCA-mutation carrier cancer patients.

Zev A. Wainberg, Saeed Rafii, Ramesh K. Ramanathan, Lida A. Mina, Lauren A. Byers
DOI: 10.1200/jco.2014.32.15_suppl.7522
Journal of Clinical Oncology

Data up to Jan 2025

Published2014
Citations37
References0
Fields
MedicineChemistryInternal medicineOncologyGastroenterology

Total Citations Per Year

Abstract

References (0)

No references found

Cited By (0)

No citing papers found in database

Safety and antitumor activity of the PARP inhibitor BMN673 in a phase 1 trial recruiting… (2014) – Journal of Clinical Oncology | Metascience Observatory Explorer